Freedom of Information Request ID
9279
Date of response
September 2024
Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
· Abatacept [Orencia]
· Adalimumab [Humira]
· Adalimumab Biosimilars
· Apremilast [Otezla]
· Baricitinib [Olumiant]
· Bimekizumab [Bimzelx]
· Certolizumab [Cimzia]
· Etanercept [Enbrel]
· Etanercept Biosimilars
· Filgotinib [Jyseleca]
· Golimumab [Simponi]
· Guselkumab [Tremfya]
· Infliximab [Remicade]
· Infliximab Biosimilars
· Ixekizumab [Taltz]
· Risankizumab [Skyrizi]
· Rituximab [MabThera]
· Rituximab Biosimilars
· Sarilumab [Kevzara]
· Secukinumab [Cosentyx]
· Tocilizumab [Ro Actemra]
· Tocilizumab Biosimilars
· Tofacitinib [Xeljanz]
· Upadacitinib [Rinvoq]
· Ustekinumab [Stelara]
· Ustekinumab Biosimilar
FOI Requests
The Freedom of Information Act 2000 provides people with a right of access to a wide range of information held by public authorities, including the NHS.
FOI Disclosure Log
A collection of the most common FOI requests we have received and responded to.